Prothena Corp Q1 2025 10-Q Filing
Ticker: PRTA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1559053
| Field | Detail |
|---|---|
| Company | Prothena Corp Public Ltd Co (PRTA) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Prothena's Q1 2025 10-Q is in. Check financials.
AI Summary
Prothena Corporation plc filed a 10-Q for the period ending March 31, 2025. The company, based in Dublin, Ireland, operates in the pharmaceutical preparations sector. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational updates for Prothena Corporation plc, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Prothena faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- PROTHENA CORP PUBLIC LTD CO (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250508 (date) — Filing Date
- Dublin (location) — Company Headquarters
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250508.
What is Prothena Corporation's primary business sector?
Prothena Corporation's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where is Prothena Corporation located?
Prothena Corporation's business and mail address is 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, L2, D02 VK60.
What is the SEC file number for Prothena Corporation?
The SEC File Number for Prothena Corporation is 001-35676.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding PROTHENA CORP PUBLIC LTD CO (PRTA).